Anagrelide Hydrochloride

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced five upcoming presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2026 Congress. The ASCO annual meeting will be held May 29-June 2 in Chicago, and the EHA2026 Congress will be held June 11-14 in Stockholm, Sweden. PharmaEssentia will present new analyses from the Phase 3 SURPASS-ET study (NCT04285086) of ropeginterferon alfa-2b in patients with essential thrombocythemia (ET), including two-year outcomes comparing early versus delayed initiation (continuous treatment from baseline vs. initiation following prior anagrelide therapy) and post-hoc analyses of patients who transitioned from anagrelide. Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi® for the treatment of adults with polycythemia vera (PV). The use of ropeginterferon alfa-2b-njft for ET is currently still investigational, but it is currently under review by FDA with a PDUFA goal date of August 30, 2026. Findings from SURPASS-ET demonstrate sustained hematologic control and progressive molecular improvement with longer interferon exposure, with deeper molecular responses and improved long-term disease control observed with earlier initiation. Patients who transitioned from anagrelide showed improved hematologic parameters over 12 weeks, supporting the feasibility of treatment transition. Importantly, estimated progression-free survival (PFS) at 24 months was 76.9% in patients who received ropeginterferon alfa-2b from baseline compared to 43.1% in those with delayed initiation. Together, these data support consideration of earlier ropeginterferon alfa-2b use in high-risk ET following hydroxyurea intolerance or resistance. PharmaEssentia will also present an integrated analysis of the SURPASS-ET and Phase 2b EXCEED-ET (NCT05482971) trials. The analysis includes 182 patients across both studies and evaluates the consistency of clinical benefit across treatment lines, including treatment-naïve and previously treated populations, as well as across molecular subtypes and ethnicities. Results demonstrated clinically meaningful hematologic and molecular responses in both treatment-naïve and pretreated patients. Efficacy was consistent across driver mutation subtypes, and the presence of additional non-driver mutations did not adversely impact outcomes. “These findings represent an important step forward in understanding the potential use of interferon-based approaches in essential thrombocythemia,” said Ruben Mesa, M.D., co-principal investigator, presenting author, and President of Advocate Health Cancer National Service Line. “Together, these data continue to build on the growing body of evidence supporting the use of ropeginterferon alfa-2b in ET and reinforce its potential role as a meaningful treatment option for patients.” In addition, PharmaEssentia will present real-world data evaluating the association between neutrophil-to-lymphocyte ratio (NLR) and thrombotic risk in 11,809 U.S. veterans with PV. An online-only abstract will also report findings from a meta-analysis evaluating dosing strategies for ropeginterferon alfa-2b in PV, suggesting that a higher initial dose with accelerated titration (HIDAT) may lead to improved early hematologic and molecular response rates compared to lower-dose currently approved regimens. Poster Presentations Title: Integrated Analysis of the Ropeginterferon alfa-2b Clinical Program in Essential Thrombocythemia to Demonstrate Molecular and Hematologic Responses with Safety Profile Across Treatment Lines, Ethnicities, and Driver Mutation Types Abstract Number: 6576 Poster: 369 Presenter: Ruben Mesa, M.D. Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: June 1st Time: 9-12 pm CDT Title: Association of neutrophil‑to‑lymphocyte ratio and thrombotic events in US Veterans with Polycythemia vera Abstract Number: 6578 Poster: 371 Presenter: Ying Wang, PhD Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: June 1st Time: 9-12 pm CDT Published Abstract Title: Effect of Higher Initial Dose and Accelerated Titration of Ropeginterferon Alfa-2b on Early Hematologic and Molecular Responses in Polycythemia Vera: A Meta-Analysis Abstract Number: e18592 EHA Oral Presentation Title: Early versus Delayed Initiation of Ropeginterferon Alfa-2b in High-Risk Essential Thrombocythaemia: Two-Year Results from the Phase 3 SURPASS-ET Study Abstract Number: S219 Presenter: Harry Gill, M.D. Session: Myeloproliferative neoplasms - Clinical Date: June 13th Time: 5:15 – 6:30 pm CEST Poster Presentations Title: Ropeginterferon alfa-2b Demonstrates Molecular and Hematologic Responses with a Favorable Safety Profile in Essential Thrombocythemia Abstract Number: PS1986 Presenter: Harry Gill, M.D. Session: Myeloproliferative neoplasms - Clinical Date: June 13th Time: 6:45 – 7:45 pm CEST Title: Hematologic Control and Improved Safety Following Switch from Anagrelide to Ropeginterferon Alfa-2b in Patients with Essential Thrombocythemia: 12-Week Pre-/Post-Switch Analysis from the SURPASS-ET study Abstract Number: PF912 Presenter: Lucia Masarova, M.D. Session: Myeloproliferative neoplasms - Clinical Date: June 12th Time: 6:45 – 7:45 pm CEST PharmaEssentia USA Corporation, located in Burlington, Massachusetts, is a subsidiary of PharmaEssentia Corporation (TWSE: 6446). PharmaEssentia Corporation, headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator and the developer and owner of BESREMi® (ropeginterferon alfa-2b-njft). Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. Essential thrombocythemia is a rare blood disorder and type of myeloproliferative neoplasm (MPN). It is characterized by the bone marrow overproducing platelets. Patients with ET are at an increased risk of blood clots, abnormal bleeding and enlarged spleens. ET is often caused by genetic mutations such as a JAK2 genetic mutation. Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi® for the treatment of adults with polycythemia vera (PV). The Company plans to seek a ropeginterferon alfa-2b-njft label expansion to include ET and has submitted a sBLA with the U.S. FDA. BESREMi® holds orphan drug designation in the United States for the treatment of polycythemia vera (PV) in adults. It has received regulatory approval in over 40 countries, including from the European Medicines Agency (2019), the U.S. Food and Drug Administration (2021), and the Pharmaceuticals and Medical Devices Agency in Japan (2023). The product was developed by PharmaEssentia. PharmaEssentia retains full global intellectual property rights across all indications. The content above comes from the network. if any infringement, please contact us to modify.

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。 Atacicept | 阿塞西普 MCE 国际站：Atacicept 品牌：MedChemExpress (MCE) 货号：HY-P99446 CAS：845264-92-8 中文名称：阿塞西普 Synonyms：阿塞西普; TACI-Ig; TACI-Fc 5 纯度：99.5% 存储条件：请将产品存放在分析证书上推荐的条件下。 运输条件：用干冰运输。 产品活性：Atacicept (TACI-Ig) 是一种重组融合蛋白，包含 TACI 受体的细胞外配体结合部分和人 IgG 的 Fc 部分。Atacicept 通过结合 B 淋巴细胞刺激剂和增殖诱导配体抑制 B 细胞刺激。Atacicept 可用于 B 细胞自身免疫性疾病的研究。 生物活性：Atacicept (TACI-Ig) 是一种重组融合蛋白，含有 TACI 受体的胞外配体结合部分和人 IgG 的 Fc 部分。 Atacicept 通过与 B 淋巴细胞刺激剂和增殖诱导配体结合来抑制 B 细胞刺激。 Atacicept 可用于 B 细胞自身免疫性疾病的研究[1][2]。体内： Atacicept（TACI-Ig；100 μg；腹腔注射；每周 3 次，持续 14 天；BALB/c 小鼠）可降低正常小鼠的成熟 B 细胞计数和血清抗体水平[1]。Atacicept (TACI-Ig) 可抑制胶原诱导性关节炎 (CIA) 小鼠模型中的疾病进展和自身抗体滴度[1]。 体内：Atacicept (TACI-Ig; 100 μg; i.p.; 每周三次，共 14 天; BALB/c 小鼠) 降低正常小鼠成熟 B 细胞计数和血清抗体水平[1]。 Atacicept (100 μg; i.p.; 每周三次，共 21 天) 抑制胶原诱导性关节炎 (CIA) 小鼠模型的疾病进展和自身抗体滴度[1]。 MCE尚未独立证实这些方法的准确性。仅供参考。 种属：Human 热销产品：Insulin aspart  | Phrixotoxin-1 (TFA)  | Vilazodone (Hydrochloride)  | INDY  | Toltrazuril (sulfone)  | Anagrelide (hydrochloride)  | Cyclopentenyl uracil  | Anethole trithione  | Deoxyshikonin  | O4I4 Trending products：Recombinant Proteins  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Oligonucleotides 参考文献：[1]. Gross JA, et, al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001 Aug;15(2):289-302. [2]. Gross JA, et, al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000 Apr 27;404(6781):995-9. 品牌介绍:•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；•   设有专业的实验中心和严格的质控、验证体系；•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；•   产品的生物活性多经各国客户实验验证；•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；•   与世界各大制药公司及知名科研机构建立了长期的合作。